Literature DB >> 23332441

An iterative model for in vitro laboratory assessment of tamper deterrent formulations.

Edward J Cone1, Jennifer Giordano, Brianne Weingarten.   

Abstract

BACKGROUND: In an effort to address the continuing problem of prescription opioid abuse, manufacturers are incorporating new technologies into formulations that are designed to deter product tampering and misuse. Standards for laboratory assessment of tamper deterrent properties of new formulations have not previously been developed.
METHODS: Experimental designs were developed for the in vitro laboratory assessment of the tamper deterrent properties of reformulated oxycodone. Given that an exhaustive study of all potential tampering methods was impractical; this model was developed to evaluate the product in an incremental fashion with iterative changes that were amenable to objective and replicable laboratory testing.
RESULTS: A description of the model is provided along with pertinent examples involving assessment of reformulated oxycodone with comparisons to the original formulation. Physical and chemical procedures were developed that relate to "real-world" scenarios that may be applied to opioid formulations. Test results were interpreted in relation to the relative ease or difficulty of the manipulation as compared to control materials and the amount and purity of active drug that could be accessed. Results from some of the tests were designed to be useful in predicting whether specific tampering methods would facilitate or deter drug administration by different routes of administration.
CONCLUSIONS: This model, developed to assess the tamper deterrent properties of reformulated oxycodone, should have application in the assessment of other drug formulations designed to exhibit tamper deterrence properties.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332441     DOI: 10.1016/j.drugalcdep.2012.12.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  10 in total

Review 1.  Agonist Medications for the Treatment of Cocaine Use Disorder.

Authors:  S Stevens Negus; Jack Henningfield
Journal:  Neuropsychopharmacology       Date:  2014-12-11       Impact factor: 7.853

2.  Risk based in vitro performance assessment of extended release abuse deterrent formulations.

Authors:  Xiaoming Xu; Abhay Gupta; Manar Al-Ghabeish; Silvia N Calderon; Mansoor A Khan
Journal:  Int J Pharm       Date:  2016-01-16       Impact factor: 5.875

3.  An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose.

Authors:  Daniel C Beachler; Kelsey Hall; Renu Garg; Geetanjoli Banerjee; Ling Li; Luke Boulanger; Huseyin Yuce; Alexander M Walker
Journal:  Clin J Pain       Date:  2022-06-01       Impact factor: 3.423

4.  Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.

Authors:  Paul M Coplan; Hrishikesh Kale; Lauren Sandstrom; Craig Landau; Howard D Chilcoat
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-09-30       Impact factor: 2.890

5.  The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.

Authors:  P M Coplan; H D Chilcoat; S F Butler; E M Sellers; A Kadakia; V Harikrishnan; J D Haddox; R C Dart
Journal:  Clin Pharmacol Ther       Date:  2016-06-22       Impact factor: 6.875

6.  In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Authors:  Nancy T Crudele; Jennifer Giordano; Ram P Kapil; Amarita S Randhawa
Journal:  Pain Med       Date:  2017-05-01       Impact factor: 3.750

7.  Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone.

Authors:  Lynn Webster; Jack Henningfield; August R Buchhalter; Suresh Siddhanti; Lin Lu; Aleksandrs Odinecs; Carlo J Di Fonzo; Michael A Eldon
Journal:  Pain Med       Date:  2018-02-01       Impact factor: 3.750

Review 8.  Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Authors:  Cherkaouia Kibaly; Jacob A Alderete; Steven H Liu; Hazem S Nasef; Ping-Yee Law; Christopher J Evans; Catherine M Cahill
Journal:  Cell Mol Neurobiol       Date:  2020-11-27       Impact factor: 4.231

9.  Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.

Authors:  Stephen C Harris; Peter J Perrino; Ira Smith; Megan J Shram; Salvatore V Colucci; Cynthia Bartlett; Edward M Sellers
Journal:  J Clin Pharmacol       Date:  2013-12-11       Impact factor: 3.126

10.  Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Authors:  Nelson E Sessler; Jerod M Downing; Hrishikesh Kale; Howard D Chilcoat; Todd F Baumgartner; Paul M Coplan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-11       Impact factor: 2.890

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.